---
title: "U.S. stock market update: Vor BioPharma down 7.69%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249452122.md"
description: "Vor BioPharma fell 7.69%; AbbVie fell 1.52%, with a transaction volume of USD 422 million; Recursion Pharmaceuticals rose 11.99%, with a transaction volume of USD 419 million; SAB Biotherapeutics rose 20.23%, with a transaction volume of USD 368 million; Amgen rose 0.25%, with a market capitalization of USD 158.9 billion"
datetime: "2025-07-21T17:43:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249452122.md)
  - [en](https://longbridge.com/en/news/249452122.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249452122.md)
generator: "portal-rs"
---

# U.S. stock market update: Vor BioPharma down 7.69%

**U.S. Stock Market Midday Update**

Vor BioPharma fell 7.69%, with increased trading volume. Based on recent important news:

1.  On July 18, Vor Biopharma announced the grant of inducible stock options and restricted stock units under NASDAQ listing rule 5635(c)(4), leading to a negative market reaction to changes in the company's governance structure, resulting in a drop in stock price.

2.  On July 18, Vor Biopharma submitted an initial beneficial ownership statement, confirming Michel Detheux and Alexander Cumbo as company directors, with the market taking a wait-and-see attitude towards changes in the company's management, putting pressure on the stock price.

3.  On July 20, H.C. Wainwright analyst Swayampakula Ramakanth upgraded Vor Biopharma to a buy rating with a target price of $3, but the market lacked confidence in the company's short-term growth potential, failing to boost the stock price.

**Stocks with High Trading Volume in the Industry**

AbbVie fell 1.52%, with increased trading volume. Based on recent important news:

1.  On July 22, AbbVie's subsidiary won a patent lawsuit in the U.S., receiving $56 million in damages; however, the market still has doubts about its future profitability, leading to a 1.52% drop in stock price.

2.  On July 21, Morgan Stanley analysts reiterated a buy rating with a target price of $250, but failed to boost market confidence.

3.  On July 19, market analysis indicated that AbbVie is not on the current best buy stock list, affecting investor sentiment.

Recursion Pharmaceuticals rose 11.99%, with a trading volume of $419 million. Based on recent important news:

1.  On July 21, clinical trials for REC-3565 and REC-617 made positive progress, driving the stock price up 11.99%.

2.  On July 20, the application of AI technology in drug development enhanced market confidence in Recursion.

3.  On July 21, analysts' increased focus on value and momentum stocks improved investor sentiment.

SAB Biotherapeutics rose 20.23%, with a trading volume of $368 million. Based on recent key news:

1.  On June 26, SAB Biotherapeutics announced a $125 million paid licensing agreement with Vor Bio, driving the stock price up 20.23%.

2.  On June 23, Standard BioTools announced the sale of its Somalogic division, with the stock price rising 10%, boosting the overall biopharmaceutical sector.

3.  On June 12, China Biopharmaceutical revealed at the Goldman Sachs Global Healthcare Conference that it is about to reach a significant external licensing deal, with the stock price rising 15%, enhancing market confidence in the biopharmaceutical industry **Stocks Ranked Among the Top by Market Capitalization in the Industry**

Amgen rose 0.25%, with a market capitalization of $158.9 billion. Based on recent important news:

1.  On July 19, Amgen's research progress in the oncology market, particularly in treatments targeting KRAS mutations, may give it a competitive advantage, driving the stock price up.

2.  On July 20, analysts maintained a hold rating on Amgen, not including it in the recommended buy list, affecting market sentiment.

3.  On July 21, market attention on Amgen increased, with trading volume expanding, leading to a slight rise in the stock price

### Related Stocks

- [VOR.US](https://longbridge.com/en/quote/VOR.US.md)

## Related News & Research

- [Is Phase 3 Enrollment Complete Altering The Investment Case For Vor Biopharma (VOR)?](https://longbridge.com/en/news/299274965.md)
- [Vor Bio highlights telitacicept BAFF/APRIL inhibitor as lead program in B cell-driven autoimmune diseases](https://longbridge.com/en/news/298307942.md)
- [McDonald's Stock (MCD) Looks Tastier as It Gets Set For Another Value Meals Revamp](https://longbridge.com/en/news/299444824.md)
- [Intel (INTC) Stock Looks Above Fair Value After Its 256% Run](https://longbridge.com/en/news/299431661.md)
- [What's Going On With Sandisk Stock Friday?](https://longbridge.com/en/news/299469153.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**